Overview

Pulmovant focuses on developing mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator, as a therapy for pulmonary diseases, especially pulmonary hypertension associated with interstitial lung disease (PH-ILD). It advances mosliciguat through clinical trials with a dry powder inhaler designed for targeted delivery to the lungs to cause pulmonary vasodilation while aiming to limit systemic exposure. The company differentiates itself by pursuing a first-in-class inhaled sGC activator, leveraging Roivant’s biotech ecosystem, and seeking regulatory advantages such as orphan drug designation in Japan, to address a patient group of about 200,000 in the U.S. and Europe who have few treatment options. Pulmovant is moving mosliciguat through Phase 2 programs (PHocus and PHactor) with topline Phase 2 results anticipated in late 2026, and aims to progress toward regulatory approval and broader access for PH-ILD patients.